Citi analyst Joel Beatty raised his price target on The Medicines Co. shares to $50 as he believes the ongoing phase 3 inclisiran trial will be a success and that the drug can take significant share, if approved, because its every 6 month dosing is a significant advantage over current PCSK9s that must be dosed monthly. He also notes that sales of the two approved PCSK9 agents are accelerating and believes new cholesterol treatment guidelines will likely further drive longer-term PCSK9 growth, Beatty tells investors. He keeps a Buy rating on Medicines Co. shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.